Loading organizations...
§ Public · Cambridge, MA, USA
Biotechnology company developing potentially curative CRISPR-based genome editing therapeutics for severe genetic diseases, addressing.
Intellia Therapeutics develops potentially curative therapeutics using CRISPR-based genome editing technologies to treat severe diseases by addressing their root causes. The company focuses on clinical-stage programs leveraging the CRISPR/Cas9 system, adapted from a bacterial immune system. Its business model is supported by strategic partnerships and investments, aiming to generate value through corporate strategy and portfolio planning. John Leonard serves as CEO, with Derek Hicks as Chief Business Officer. Co-founders Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their foundational work on CRISPR. Intellia Therapeutics was founded in 2014 by Nessan Bermingham, alongside a team including Jennifer Doudna and Emmanuelle Charpentier. Its business model centers on funded through strategic partnerships and investments, generates value via corporate strategy, portfolio planning, and new business development.
Intellia Therapeutics has raised $85.0M across 2 funding rounds.
Key people at Intellia Therapeutics.
Intellia Therapeutics was founded in 2014 by Jennifer Doudna (Founder) and Erik Sontheimer (Co-Founder) and Derrick Rossi (Founder) and Luciano Marraffini (Founder & Advisor) and Rodolphe Barrangou (Co-Founder).
Intellia Therapeutics has raised $85.0M in total across 2 funding rounds.
Intellia Therapeutics was founded in 2014 by Jennifer Doudna (Founder) and Erik Sontheimer (Co-Founder) and Derrick Rossi (Founder) and Luciano Marraffini (Founder & Advisor) and Rodolphe Barrangou (Co-Founder).
Intellia Therapeutics has raised $85.0M in total across 2 funding rounds.
Intellia Therapeutics's investors include OrbiMed, Aisling Capital, Atlas Venture, General Atlantic, The Column Group, EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Janus Henderson Investors, Novartis, Sectoral Asset Management.
Key people at Intellia Therapeutics.
Intellia Therapeutics has raised $85.0M across 2 funding rounds. Most recently, it raised $70.0M Series B in August 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2015 | $70M Series B | OrbiMed | Aisling Capital, Atlas Venture, General Atlantic, The Column Group, EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Janus Henderson Investors, Novartis, Sectoral Asset Management | Announced |
| Nov 1, 2014 | $15M Series A | — | Atlas Venture | Announced |
Intellia Therapeutics is a clinical-stage biotechnology company pioneering CRISPR/Cas9-based genome editing to develop potentially curative therapies for severe genetic diseases.[1][2][3][4] It targets conditions like hereditary angioedema (HAE) with NTLA-2002 and transthyretin (ATTR) amyloidosis with nexiguran ziclumeran (nex-z), addressing unmet needs by editing disease-causing genes directly in the body rather than managing symptoms.[1][4] The company serves patients with life-threatening disorders, leveraging partnerships like Regeneron for in vivo delivery, with significant R&D investment—$481.7 million in fiscal 2024—fueling a pipeline of transformative programs.[1]
Intellia Therapeutics was founded in 2014 by pioneers in CRISPR/Cas9 technology, driven by the belief that this system could permanently edit disease-associated genes with a single treatment.[2][3] The idea emerged from the rapid advancement of CRISPR as a precise, programmable tool for gene editing, offering hope for curing chronic conditions where prior options failed.[3] Early traction came from assembling deep scientific expertise, a leading IP portfolio, and strategic collaborations, positioning Intellia to translate CRISPR from lab discovery to clinic—evidenced by advancing late-stage programs like nex-z, with positive Phase 1 data in ATTR amyloidosis patients.[1][4]
Intellia rides the gene editing revolution, harnessing CRISPR's simplicity, specificity, and programmability to unlock cures for genetic disorders amid rising demand for precision medicine.[2][3] Timing aligns with maturing CRISPR tech, regulatory progress (e.g., first approvals), and market forces like aging populations driving ATTR and HAE needs.[1][4] It influences the ecosystem by validating in vivo editing, inspiring competitors, and expanding CRISPR beyond ex vivo cell therapies into mainstream oncology and rare diseases.[2]
Intellia is poised to deliver first-in-class approvals for nex-z and NTLA-2002, potentially establishing CRISPR as a blockbuster platform with durable revenue from one-time dosing.[1][4] Trends like AI-optimized editing, expanded delivery tech, and combo therapies will accelerate its pipeline into new indications, while partnerships mitigate cash burn. Its influence could grow by democratizing curative gene edits, transforming biotech from symptom relief to root-cause cures—cementing its role as a genome editing trailblazer.[2][3]